SenesTech highlights Q2 revenue up 56% to $770K in rodent birth control investor deck

Reuters2026/09/11 20:09

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

SenesTech outlined its commercial rebuild around rodent birth control products Evolve and ContraPest, shifting toward a revenue-driven, data-led model.
Q2 2026 revenue reached $770K, up 56% quarter-on-quarter, with gross margin of 73.6%.
E-commerce revenue rose to $511K, up 186% quarter-on-quarter, led by Amazon revenue of $349K, up 473%.
Direct-to-consumer subscription revenue increased to $104K, up 89% quarter-on-quarter, representing 13.5% of quarterly revenue.
Management highlighted a $1.8-2.0B U.S. market within a $4.5B-plus global opportunity, citing 95% lower rodent activity by month 13.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SenesTech Inc. published the original content used to generate this news brief on September 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

SenesTech highlights Q2 revenue up 56% to $770K in rodent birth control investor deck

You may also like

Crypto prices